QIAGEN

Name: QIAGEN
Address: Qiagen Str. 1, Hilden, 40724, DE
Telephone: +492103290
Price range: ££

QIAGEN is the leading provider of sample to insight solutions. Everyone has the right to express their own opinion
• Respecting the rights of others

2.

Links to websites are provided for convenience and do not imply sponsorship, affiliation or endorsement. Guidelines when using our page

We ask that you please adhere to the following guidelines when using our page:

1. Netiquette

Posting and commenting on our page should follow these general communications rules:

• Treating all other users as you would like to be tre

ated by them
• Respecting the opinions of others and not trying to force your opinion on anyone else. Deletion of posts/comments and blocking Facebook accounts

The following actions are examples that are seen as violations of the terms of use. These actions will result in the immediate deletion of posts/comments or, in the case of gross or repeated violations, we will block the user so that he or she is not able to post further content or comments on our page:

• Personal insults or degrading comments of any kind
• Defamatory, anti-constitutional, racist, or pornographic statements or illustrations
• Disparaging comments about institutions, organizations or companies, sexist or racist comments, or hate propaganda
• Any violation of the rights of third parties, in particular copyrights
• Comments that do not relate to the messages under discussion or that are off-topic
• Attacking others or calling for violence of any kind
• Calls to join in demonstrations or rallies of any political orientation
• Offering goods or services, of either a commercial or private nature, or using this page as an advertising space
• Spam, i.e., any form of automatically generated content or repeatedly posting the same comment

3. Privacy policy

We created this page in order to connect and facilitate with interested people an exchange about science, biotechnology, healthcare, molecular diagnostics, and other QIAGEN-related topics. The Privacy Policy covers how we handle personal data, which is submitted to Facebook by clicking the “Like” button on our page. This data is also accessible to QIAGEN. The data we receive from Facebook contains:

• Age demographics
• Place of residence (country and city)
• Gender
• Language
• Activity statistics/rate of all people using our page

Facebook provides this data exclusively in a summarized form. QIAGEN does not receive data on individuals or small user groups. We don’t share the data with third parties. User data is used exclusively to administer our page and to learn more about which topics are of interest to our followers so that we can further improve our page’s offering.

4. Disclaimer

The messages posted in response to our articles reflect the opinions of individual members only. We are not liable for the content of any messages, or for conclusions that may be drawn from such messages. QIAGEN makes no representations or warranties of any kind about the accuracy or completeness of the content.

01/06/2026

We are stepping up to support infectious disease research and surveillance efforts for the Bundibugyo ebolavirus outbreak. Learn more 👉 https://tinyurl.com/42jyph3h

As reliable genomic data becomes available, laboratories need flexible tools they can evaluate and slot into their existing workflows.

✅ Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

✅ Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

✅ Our broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available. Our goal remains clear: no country should be left behind when new threats emerge.

These assays are intended for research use only and are not intended for diagnostic procedures.

26/05/2026

Running a high-throughput clinical lab means striving to deliver results with high sensitivity and high accuracy, which all starts with reliable sample extraction. But what if your extraction process could deliver even more?

Automation has always been central to fast-paced clinical testing labs, who are under immense pressure to deliver results with confidence despite rising sample numbers. More samples mean productivity is stretched and sample traceability becomes more complex. Smart automation that can quickly adapt to changing needs, whether it's input volumes, applications or even sample numbers, is the future.

A new IVD automated sample extraction platform is on the horizon, designed to support clinical testing by combining:

✅High DNA/RNA yields for increased downstream assay sensitivity
✅Fast, efficient workflows that boost productivity
✅Simplified sample tracking and seamless digital integration
✅A future-proof platform built to scale with your lab

One system. Multiple applications. Consistent performance you can trust. Automated sample extraction that always ends on a high note. See what's next ➡️ https://tinyurl.com/msase86x

21/05/2026

We are thrilled to announce the global launch of QIA Agent, our new AI-powered digital assistant, now live on qiagen.com. Try it now 👉 https://tinyurl.com/3nkpzc6m

QIA Agent connects researchers to the scientific guidance, product information and workflow support they need, all through a single conversational interface.

✅ Connects experiment planning, product discovery and workflow support through a single conversational interface

✅ Helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

✅ Expands our digital ecosystem with AI-driven workflow support embedded directly into the customer experience

With more than 260,000 users already registered on My QIAGEN, QIA Agent builds on an established digital customer base to help researchers move faster from questions to decisions across Sample to Insight workflows.

19/05/2026

We are excited to announce a new collaboration with NVIDIA to advance AI-driven drug discovery. Learn more 👉 https://tinyurl.com/3kwfrc3h

Drug discovery depends on connecting complex biological data across genes, diseases, pathways, compounds and clinical evidence. Together with NVIDIA, we are combining QIAGEN Digital Insights' curated biomedical knowledge bases with the NVIDIA BioNeMo platform to help researchers get from data to discovery decisions faster.

Here's what this collaboration brings to the bench:

✅ Integrate NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases

✅ Jointly advance how disease mechanisms, therapeutic targets and biomarkers are identified

✅ Explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence using a graph-based AI approach

✅ Join initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation

13/05/2026

We're excited to share that our newly launched QIAsprint Connect has received the prestigious Red Dot Design Award, marking the fifth time a QIAGEN instrument has earned this global recognition.

✅ QIAsprint Connect delivers high-throughput nucleic acid extraction with up to 192 samples per run, all in a compact benchtop footprint. With built-in decontamination control, validated and customizable protocols accessible via an intuitive touchscreen and digital connectivity for remote run monitoring, it helps labs maximize walk-away efficiency and ease of use.

✅ It also introduces a novel consumables concept that reduces plastic use by up to 50% and packaging volume by 40% compared to standard market consumables, helping labs scale more sustainably without compromising performance.

The Red Dot jury recognized QIAsprint Connect for its user-centric functionality and design, reflecting how modern lab instruments should integrate into increasingly digital, high-throughput environments.

This award reinforces our commitment to solutions that don't just fit on your lab bench but also perform better and elevate the everyday lab experience.

12/05/2026

Looking to get more from your targeted sequencing workflows?

Join our Targeted Sequencing Focus Day to learn how to:

✅ Improve efficiency, data quality, and flexibility
✅ Overcome sequencing bottlenecks
✅ Choose the right strategy for your lab

Sign up now for this free online event 👉 https://tinyurl.com/3w6pvusa

07/05/2026

We are excited to announce two major innovations coming to QuantiFERON latent TB testing: a fully automated Sample to Insight workflow and an AI-enabled risk stratification tool, both targeted for late 2027. Learn more 👉 https://tinyurl.com/ysreje89

As TB screening volumes continue to grow, high-throughput laboratories need solutions that scale efficiently. Here's what's coming:

✅ A fully automated end-to-end workflow integrating QuantiFERON, Diasorin LIAISON systems and purpose-built automation through our new Inpeco partnership

✅ An AI-enabled risk stratification tool for TB progression designed to support informed clinical decision-making for all QuantiFERON customers

✅ New QuantiFERON LIAISON chemistry developed by Diasorin being rolled out to customers, delivering significant throughput and workflow benefits

04/05/2026

If TB infection testing is part of your daily practice, you can’t miss this.

Our free interactive e-book walks you through how to identify risk groups, choose the right test and improve testing accuracy using QuantiFERON-TB Gold Plus. Download your copy here: https://tinyurl.com/yd39c5ut

You’ll get clear, evidence-based recommendations to help you:

✅ Focus on the patients who need testing most – from recent immigrants and healthcare workers to children, dialysis patients and those on immunosuppressive therapy. Intervene before infection progresses.

✅ Confidently choose between TST and IGRA – with a simple breakdown of accuracy, BCG impact and workflow differences. Make testing decisions with clarity.

✅ Align with trusted guidance – bringing CDC, ATS, IDSA and WHO recommendations together in one place. Keep screening and follow-up aligned with best practices.

Because early and accurate TB infection detection has the power to change outcomes.

29/04/2026

What if clinical labs could increase their syndromic testing capabilities without adding additional complexity?

We’ve made that possible with our fully automated, high-throughput syndromic testing platform, QIAstat-Dx Rise. An expanded testing menu, now including FDA-cleared gastrointestinal (GI) panels, enables labs to consolidate both respiratory (RP) and GI pathogen testing into a single platform for comprehensive disease insights.

What does this mean for your lab?

✅ Accurate detection of the most clinically-relevant RP and GI pathogens
✅ Testing flexibility with access to both extended and targeted syndromic panels
✅ True walkaway freedom due to minimal hands-on time
✅ Results in about an hour to support timely clinical decisions

Discover how QIAstat Dx-Rise can transform gastrointestinal care. ➡️ https://tinyurl.com/3ddns3cx

28/04/2026

How many steps in your cell and gene therapy (CGT) workflow are you truly confident in and how many are you just hoping will work?

In cell and gene therapy development, your workflow needs to deliver every step of the way.

At ISCT 2026 (May 6-9, Dublin), explore how automation and digital PCR can help you improve consistency, reduce variability and move forward with confidence.

🔬 QIAsprint® Connect Automated high-throughput nucleic acid extraction system that offers compliance-ready flexibility for downstream molecular analysis

📊 QIAcuity® Digital PCR Precise, reproducible quantification for CGT analytics, enabling confident assessment of critical quality attributes

📍 Booth 1908 🎤 May 7 | Global Showcase presentation on CAR T analytics presented by Anida Mesihovic Karamitsos, PhD (QIAGEN) and Arvind M. Padma, PhD (CCRM Nordic)

Adresse

Qiagen Str. 1
Hilden
40724

Telefon

+492103290

Webseite

http://www.qiagen.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von QIAGEN erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.